STOKE THERAPEUTICS INC (STOK) Stock Fundamental Analysis
USA - NASDAQ:STOK - US86150R1077 - Common Stock
32.28 USD
+0.59 (+1.86%)
32.28 USD
0 (0%)
Taking everything into account, STOK scores 5 out of 10 in our fundamental rating. STOK was compared to 534 industry peers in the Biotechnology industry. STOK is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. STOK has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year STOK was profitable.
In the past year STOK had a positive cash flow from operations.
STOK had negative earnings in each of the past 5 years.
In the past 5 years STOK always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 13.65%, STOK belongs to the best of the industry, outperforming 95.13% of the companies in the same industry.
STOK has a better Return On Equity (15.67%) than 94.76% of its industry peers.
STOK's Return On Invested Capital of 9.20% is amongst the best of the industry. STOK outperforms 93.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.65% | ||
| ROE | 15.67% | ||
| ROIC | 9.2% |
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
STOK has a better Profit Margin (26.26%) than 95.88% of its industry peers.
With an excellent Operating Margin value of 20.15%, STOK belongs to the best of the industry, outperforming 94.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.15% | ||
| PM (TTM) | 26.26% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
STOK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for STOK has been increased compared to 1 year ago.
The number of shares outstanding for STOK has been increased compared to 5 years ago.
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 21.54 indicates that STOK is not in any danger for bankruptcy at the moment.
STOK has a Altman-Z score of 21.54. This is amongst the best in the industry. STOK outperforms 91.39% of its industry peers.
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 21.54 |
ROIC/WACC0.98
WACC9.36%
2.3 Liquidity
STOK has a Current Ratio of 6.98. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
STOK has a better Current ratio (6.98) than 69.10% of its industry peers.
STOK has a Quick Ratio of 6.98. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of STOK (6.98) is better than 69.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.98 | ||
| Quick Ratio | 6.98 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 142.58% over the past year.
The Revenue has grown by 1218.65% in the past year. This is a very strong growth!
EPS 1Y (TTM)142.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)1218.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.01%
3.2 Future
The Earnings Per Share is expected to grow by 16.02% on average over the next years. This is quite good.
Based on estimates for the next years, STOK will show a very strong growth in Revenue. The Revenue will grow by 68.28% on average per year.
EPS Next Y117.64%
EPS Next 2Y-30.95%
EPS Next 3Y-16.29%
EPS Next 5Y16.02%
Revenue Next Year914.78%
Revenue Next 2Y31.67%
Revenue Next 3Y35.53%
Revenue Next 5Y68.28%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 34.71, which means the current valuation is very expensive for STOK.
STOK's Price/Earnings ratio is rather cheap when compared to the industry. STOK is cheaper than 92.88% of the companies in the same industry.
STOK is valuated rather expensively when we compare the Price/Earnings ratio to 26.89, which is the current average of the S&P500 Index.
STOK is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.71 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, STOK is valued cheaply inside the industry as 92.32% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, STOK is valued cheaper than 94.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.93 | ||
| EV/EBITDA | 32.53 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
STOK's earnings are expected to decrease with -16.29% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y-30.95%
EPS Next 3Y-16.29%
5. Dividend
5.1 Amount
STOK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
32.28
+0.59 (+1.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners118.79%
Inst Owner Change0.5%
Ins Owners4.3%
Ins Owner Change-28.1%
Market Cap1.77B
Revenue(TTM)199.89M
Net Income(TTM)52.48M
Analysts84.71
Price Target24.71 (-23.45%)
Short Float %20.59%
Short Ratio9.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)291.04%
Min EPS beat(2)23.41%
Max EPS beat(2)558.67%
EPS beat(4)4
Avg EPS beat(4)165.54%
Min EPS beat(4)13.51%
Max EPS beat(4)558.67%
EPS beat(8)8
Avg EPS beat(8)88.85%
EPS beat(12)11
Avg EPS beat(12)62.04%
EPS beat(16)12
Avg EPS beat(16)29.4%
Revenue beat(2)2
Avg Revenue beat(2)863.06%
Min Revenue beat(2)52.02%
Max Revenue beat(2)1674.1%
Revenue beat(4)4
Avg Revenue beat(4)546.83%
Min Revenue beat(4)43.23%
Max Revenue beat(4)1674.1%
Revenue beat(8)7
Avg Revenue beat(8)280.95%
Revenue beat(12)10
Avg Revenue beat(12)183.53%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.04%
EPS NY rev (1m)0%
EPS NY rev (3m)384.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-29.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.71 | ||
| Fwd PE | N/A | ||
| P/S | 8.85 | ||
| P/FCF | 28.93 | ||
| P/OCF | 28.72 | ||
| P/B | 5.28 | ||
| P/tB | 5.28 | ||
| EV/EBITDA | 32.53 |
EPS(TTM)0.93
EY2.88%
EPS(NY)-2.88
Fwd EYN/A
FCF(TTM)1.12
FCFY3.46%
OCF(TTM)1.12
OCFY3.48%
SpS3.65
BVpS6.11
TBVpS6.11
PEG (NY)0.3
PEG (5Y)N/A
Graham Number11.31
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.65% | ||
| ROE | 15.67% | ||
| ROCE | 11.65% | ||
| ROIC | 9.2% | ||
| ROICexc | 32.43% | ||
| ROICexgc | 32.43% | ||
| OM | 20.15% | ||
| PM (TTM) | 26.26% | ||
| GM | N/A | ||
| FCFM | 30.59% |
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 22.67% | ||
| Cap/Sales | 0.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 145.71% | ||
| Profit Quality | 116.5% | ||
| Current Ratio | 6.98 | ||
| Quick Ratio | 6.98 | ||
| Altman-Z | 21.54 |
F-Score8
WACC9.36%
ROIC/WACC0.98
Cap/Depr(3y)110.09%
Cap/Depr(5y)114.39%
Cap/Sales(3y)16.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)142.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y117.64%
EPS Next 2Y-30.95%
EPS Next 3Y-16.29%
EPS Next 5Y16.02%
Revenue 1Y (TTM)1218.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.01%
Revenue Next Year914.78%
Revenue Next 2Y31.67%
Revenue Next 3Y35.53%
Revenue Next 5Y68.28%
EBIT growth 1Y135.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year110.74%
EBIT Next 3Y-11.06%
EBIT Next 5Y21.61%
FCF growth 1Y167.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y170.32%
OCF growth 3YN/A
OCF growth 5YN/A
STOKE THERAPEUTICS INC / STOK FAQ
What is the fundamental rating for STOK stock?
ChartMill assigns a fundamental rating of 5 / 10 to STOK.
What is the valuation status for STOK stock?
ChartMill assigns a valuation rating of 4 / 10 to STOKE THERAPEUTICS INC (STOK). This can be considered as Fairly Valued.
Can you provide the profitability details for STOKE THERAPEUTICS INC?
STOKE THERAPEUTICS INC (STOK) has a profitability rating of 4 / 10.
What is the valuation of STOKE THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for STOKE THERAPEUTICS INC (STOK) is 34.71 and the Price/Book (PB) ratio is 5.28.